We believed that CHT can be an effective treatment strategy for patients with pT1 bladder cancer, especially for patients with high-grade UC, although IVI with BCGwas considered the first-line treatment for high-risk tumors and CIS, but in this study, we demonstrated that CHT was much more effective, safer and could reduce the costs compared with BCG. The results areencouraging and further researches are needed.